MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 129 filers reported holding MERSANA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $82,591 | -35.0% | 65,032 | +68.4% | 0.00% | – |
| Q2 2023 | $127,047 | -5.8% | 38,616 | +17.7% | 0.00% | – |
| Q1 2023 | $134,853 | -30.8% | 32,811 | -1.4% | 0.00% | – |
| Q4 2022 | $194,980 | -94.9% | 33,273 | -94.1% | 0.00% | -100.0% |
| Q3 2022 | $3,795,000 | +2711.1% | 561,274 | +1822.8% | 0.00% | – |
| Q2 2022 | $135,000 | +12.5% | 29,190 | -2.9% | 0.00% | – |
| Q1 2022 | $120,000 | -35.1% | 30,068 | +1.2% | 0.00% | – |
| Q4 2021 | $185,000 | -38.9% | 29,718 | -7.7% | 0.00% | – |
| Q3 2021 | $303,000 | -17.7% | 32,211 | +19.1% | 0.00% | – |
| Q2 2021 | $368,000 | -94.5% | 27,045 | -93.4% | 0.00% | -100.0% |
| Q1 2021 | $6,670,000 | -81.2% | 412,170 | -69.0% | 0.00% | -80.0% |
| Q4 2020 | $35,407,000 | +70.2% | 1,330,589 | +19.1% | 0.01% | +42.9% |
| Q3 2020 | $20,806,000 | -9.5% | 1,117,416 | +13.7% | 0.01% | -12.5% |
| Q2 2020 | $22,998,000 | – | 982,795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 5,000,000 | $6,350,000 | 1.92% |
| VR Adviser, LLC | 11,328,000 | $14,386,560 | 1.51% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $11,002,865 | 1.23% |
| Affinity Asset Advisors, LLC | 2,850,000 | $3,619,500 | 1.02% |
| EcoR1 Capital, LLC | 19,364,688 | $24,593,154 | 0.83% |
| Altium Capital Management LP | 1,059,136 | $1,345,103 | 0.70% |
| 5AM Venture Management, LLC | 1,305,000 | $1,657,350 | 0.48% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $1,148,420 | 0.38% |
| COMMODORE CAPITAL LP | 2,244,378 | $2,850,360 | 0.33% |
| Philosophy Capital Management LLC | 2,342,634 | $2,975,145 | 0.32% |